An PMS2 genetic test looks for an inherited change in the PMS2 gene that prevents DNA mismatch repair from working normally. A pathogenic germline variant can cause Lynch syndrome, an inherited cancer-predisposition condition best known for colorectal and endometrial cancer. The test usually uses blood or saliva and should not be confused with tumor-only testing, which may find an acquired PMS2 change that is present in cancer cells but not throughout the body.
A positive result can change colonoscopy timing, prevention choices, cancer treatment context, and testing recommendations for relatives. A negative result is most informative when the laboratory checks sequencing and large deletions or duplications and when a known family variant has already been identified. A variant of uncertain significance does not confirm Lynch syndrome and should not be used by itself for preventive surgery. Tumor screening with mismatch repair immunohistochemistry or microsatellite instability can point toward PMS2, but germline testing is needed to establish an inherited diagnosis.
- A pathogenic or likely pathogenic PMS2 variant can confirm Lynch syndrome in the right clinical setting.
- Each child, sibling, or parent of a carrier may have a 50% chance of carrying the same autosomal dominant variant.
- Tumor loss of isolated loss of PMS2, although MLH1/PMS2 loss more often points toward MLH1 inactivation can guide testing but is not identical to a germline result.
- A negative test does not erase a strong family history unless it is a true negative for a known familial variant.
- A VUS is an uncertain finding, not a positive Lynch syndrome diagnosis.
- Cancer-risk estimates and surveillance differ among MLH1, MSH2, MSH6, and PMS2.
Table of Contents
- What the PMS2 Gene Does
- Who May Need PMS2 Testing
- How the Test Is Performed
- Understanding PMS2 Test Results
- Cancer Risks With a Pathogenic Variant
- Screening, Prevention, and Treatment
- What Results Mean for Relatives
- Limitations and Next Steps
What the PMS2 Gene Does
PMS2 is one of the genes that helps cells repair copying errors in DNA. During normal cell division, the mismatch repair system checks newly copied DNA for incorrect bases and small insertion or deletion loops. The PMS2 protein works closely with MLH1 and other repair proteins to recognize or correct these mistakes. When both working copies of a mismatch repair gene are lost in a cell, errors accumulate, especially in repeated DNA regions called microsatellites.
A person with Lynch syndrome is born with one nonworking copy of PMS2 in almost every cell. That inherited change is called a germline pathogenic variant. The other copy can continue to support repair for years. If a colon, endometrial, or other cell later loses its remaining working copy, mismatch repair can fail and the cell may progress toward cancer. This “two-hit” process explains why a carrier has increased risk but is not born with cancer and may never develop it.
Defective mismatch repair often produces microsatellite instability and an unusually high number of small mutations. The tumor can also lose detectable mismatch repair protein staining. A pathologist may therefore use MSI and mismatch repair testing in a colorectal, endometrial, or other tumor as an initial Lynch syndrome screen. These tumor tests examine cancer biology. They do not directly show whether the cause was inherited.
The staining pattern helps narrow the likely gene because mismatch repair proteins function in pairs. With PMS2, a characteristic pattern is isolated loss of PMS2, although MLH1/PMS2 loss more often points toward MLH1 inactivation. That pattern can result from a germline variant, two acquired changes limited to the tumor, or another gene-specific mechanism. PMS2 testing is technically demanding because a nearby pseudogene, PMS2CL, shares highly similar DNA sequence. Reliable laboratories use methods such as long-range PCR, carefully designed next-generation sequencing, and deletion/duplication analysis to distinguish the true gene. Isolated PMS2 loss can result from PMS2 itself or, less often, an MLH1 alteration that preserves MLH1 staining.
Lynch syndrome is inherited in an autosomal dominant manner. One pathogenic copy is enough to raise cancer risk, and each pregnancy has a 50% chance of passing it on. Rarely, a child inherits pathogenic variants in both copies of the same mismatch repair gene, causing constitutional mismatch repair deficiency. That severe childhood condition is distinct from typical adult Lynch syndrome and requires specialized counseling.
Who May Need PMS2 Testing
Testing may be offered after an abnormal tumor screen, a personal cancer history, a family history, or a known variant in a relative. Universal mismatch repair screening of newly diagnosed colorectal and endometrial cancers finds many candidates who would be missed by age and family-history rules alone.
Common reasons for referral include:
- a colorectal or endometrial tumor with abnormal mismatch repair staining or high microsatellite instability;
- colorectal, endometrial, ovarian, stomach, small-bowel, urinary tract, pancreatic, biliary tract, brain, prostate, or sebaceous skin cancer at an unusually young age;
- more than one Lynch-spectrum cancer in one person;
- several relatives on the same side of the family with related cancers;
- a family member with a pathogenic PMS2 variant;
- a calculated Lynch syndrome probability high enough to justify germline testing; or
- tumor sequencing that reports a potentially germline PMS2 variant.
Clinical criteria can support referral, but a family does not need to meet the Amsterdam or Bethesda criteria for testing to be appropriate. Small families, adoption, few female or male relatives, early deaths, and incomplete records can hide a hereditary pattern. Conversely, several common cancers in a large family can occur by chance. A genetics professional weighs diagnoses, ages, pathology, ancestry, and which side of the family is affected.
When possible, testing begins with a relative who has had a Lynch-associated cancer. An affected person is more likely to reveal the familial cause. Testing an unaffected relative first can produce an uninformative negative result because no one knows whether the family’s cancers were caused by PMS2, another gene, or noninherited factors.
Many laboratories use a hereditary cancer panel rather than a single-gene assay. A panel can examine PMS2, the other mismatch repair genes, EPCAM, and other colorectal or endometrial cancer genes at the same time. This is useful when the tumor pattern is unclear or the family could fit more than one syndrome. The tradeoff is a greater chance of an unexpected finding or VUS. The broader hereditary cancer panel should be chosen with informed consent about those possibilities.
How the Test Is Performed
Germline PMS2 testing usually uses a blood sample. Saliva or a cheek swab may be acceptable, although blood can be preferable when sample quality is important. No fasting is required. The laboratory extracts DNA and evaluates the coding regions and nearby splice boundaries, then checks for larger deletions or duplications that sequencing alone may miss.
A complete order should state whether a known familial variant is being tested, whether the person has active blood cancer, and whether they have received an allogeneic stem-cell transplant. Blood from a person with a hematologic malignancy can contain acquired variants, and donor-derived blood after transplant may not represent the patient’s inherited DNA. A genetics team may recommend cultured skin fibroblasts or another nonblood source in those situations.
Testing methods include next-generation sequencing, Sanger confirmation, copy-number analysis, and specialized assays for technically difficult regions. Laboratory reports should use standard variant nomenclature and a five-tier classification: pathogenic, likely pathogenic, uncertain significance, likely benign, or benign. Pathogenic and likely pathogenic findings are generally managed the same way clinically.
Tumor testing follows a different pathway. Immunohistochemistry measures MLH1, MSH2, MSH6, and PMS2 protein expression. MSI testing measures instability in repeat regions. Paired tumor-normal sequencing can look for both inherited and tumor-acquired variants. The Lynch syndrome genetic testing pathway often combines these tools because no single result answers every question.
Turnaround time ranges from roughly two to several weeks. Urgent testing may be available when the result could influence immediate surgery, systemic therapy, or treatment of a newly diagnosed cancer. Before testing, informed consent should cover medical implications, family communication, privacy protections, insurance limitations, reproductive choices, and the chance of uncertain or secondary findings.
Understanding PMS2 Test Results
A result is interpreted against the laboratory’s evidence, the person’s history, and whether a familial variant is known.
| Result | What it usually means | Typical response |
|---|---|---|
| Pathogenic or likely pathogenic | The variant disrupts PMS2 and supports a diagnosis of Lynch syndrome. | Use gene-specific surveillance, discuss prevention, and offer targeted testing to relatives. |
| Negative for a known family variant | The person did not inherit the established familial cause. | Usually return to screening based on personal history and general population guidance. |
| Negative with no known family variant | No reportable cause was found, but hereditary risk may remain unexplained. | Base care on personal and family history; consider testing another affected relative or updated testing. |
| Variant of uncertain significance | Evidence is insufficient to label the change harmful or harmless. | Do not use the VUS alone for surgery or predictive testing; monitor for reclassification. |
| Benign or likely benign | The change is not considered a cause of Lynch syndrome. | No Lynch-specific action is based on that variant. |
A positive germline result does not diagnose cancer. It identifies inherited susceptibility. A carrier still needs age-appropriate evaluation, and symptoms require normal diagnostic workup. Likewise, a positive tumor-only PMS2 result does not automatically mean Lynch syndrome. Two somatic hits can disable mismatch repair only in the tumor, a situation sometimes called double-somatic mismatch repair deficiency.
A negative result can be strongly reassuring when it is a true negative for the exact pathogenic variant already documented in the family. It is less definitive when the family has no known cause. The test may not detect deep intronic changes, low-level mosaicism, epigenetic alterations, or variants outside the assay’s design. The family’s cancers may also be caused by another gene.
A VUS should remain medically neutral. Laboratories classify it because available population, functional, segregation, and clinical evidence conflict or remain incomplete. Most VUS findings are eventually downgraded rather than upgraded. Testing healthy relatives solely to see who shares a VUS usually does not clarify risk unless a genetics team arranges a structured segregation study.
Reports can change as evidence grows. Keep a copy of the exact variant notation and laboratory name, and make sure the ordering clinic has current contact information. Periodic review is especially helpful after a VUS, an older limited test, or a negative result in a family with a strong cancer pattern.
Cancer Risks With a Pathogenic Variant
PMS2 generally has the lowest penetrance of the four classic Lynch syndrome mismatch repair genes. Lifetime colorectal cancer estimates are often around 9% to 20%, and endometrial cancer estimates around 13% to 26%. Evidence for large increases in ovarian, stomach, urinary tract, and several other Lynch-spectrum cancers is weaker than for MLH1 or MSH2, although individual family history can still be important.
PMS2 carriers usually face a more moderate colorectal and endometrial cancer risk than carriers of MLH1 or MSH2 variants. That difference affects the starting age and intensity of surveillance, but it does not make a pathogenic PMS2 result harmless.
Risk numbers are estimates, not predictions for one person. Studies differ in how families were selected, whether they corrected for referral bias, how long carriers were followed, and whether participants received colonoscopy. A person’s sex, age, family history, prior cancers, reproductive organs, smoking, body weight, and other exposures also affect absolute risk.
The most reliable message is that PMS2 risk is gene-specific and age-specific. Older descriptions often combined all Lynch syndrome genes and produced ranges that are too broad for individual counseling. Modern management increasingly separates MLH1, MSH2, MSH6, and PMS2. Because average onset is later and risk is lower, colonoscopy often starts around age 30 to 35, though an earlier family diagnosis can shift the schedule.
Colorectal cancer may arise more quickly from a precursor lesion in Lynch syndrome than in average-risk adults, which is why one- or two-year colonoscopy intervals are used rather than a ten-year interval. Colonoscopy lowers risk by finding and removing polyps and by detecting cancers earlier, but it does not reduce risk to zero.
Endometrial cancer can be the first Lynch-associated cancer. Abnormal uterine bleeding, bleeding after menopause, persistent watery or bloody discharge, or unexplained pelvic symptoms need prompt evaluation. Routine endometrial biopsy is offered in some programs, but evidence that screening reduces mortality is limited. Risk-reducing hysterectomy provides stronger prevention after childbearing for appropriately selected carriers.
Other organ risks are smaller and less certain. Screening recommendations therefore depend on the gene, family history, country, and available expertise. Broad whole-body scanning or frequent tumor-marker blood tests have not been shown to provide reliable Lynch syndrome surveillance.
Screening, Prevention, and Treatment
Many guidelines recommend colonoscopy every one to two years beginning around age 30 to 35 for PMS2 carriers, adjusted to family history. Gynecologic counseling remains appropriate, while preventive ovary removal and screening for other organs are more individualized because evidence for some extra-colonic risks is limited.
High-quality colonoscopy means complete examination to the cecum, careful inspection, good bowel preparation, and prompt removal of polyps. The next interval may shorten after a cancer, advanced adenoma, inadequate preparation, or concerning symptoms. A pathogenic result should be entered into the medical record so future clinicians do not apply average-risk intervals.
Aspirin can reduce colorectal cancer incidence in Lynch syndrome, but the optimal dose and duration remain under study. Benefits appear after years, while bleeding risk starts immediately. A clinician should review ulcers, anticoagulants, kidney disease, age, and cardiovascular factors before recommending a dose. Aspirin is not a substitute for colonoscopy.
For people with a uterus and ovaries, counseling includes symptom awareness, reproductive plans, menopause effects, and timing of preventive surgery. Hysterectomy prevents endometrial cancer. Whether and when to remove the ovaries is more gene-specific because ovarian risk is not equal across the mismatch repair genes. Premenopausal ovary removal causes immediate menopause and requires discussion of bone, heart, sexual, and quality-of-life effects.
Additional surveillance may include upper endoscopy in families with gastric cancer or higher-risk ancestry, urinary tract evaluation in selected families, annual skin examination for sebaceous tumors, and pancreatic screening only in specialized programs for carriers with qualifying family history. These options should not distract from colonoscopy, which has the strongest evidence.
If cancer develops, mismatch repair deficiency can affect treatment. MSI-high or dMMR tumors may respond to immune checkpoint inhibitors in several advanced and selected earlier-stage settings. Surgery for colon cancer may also be tailored to the risk of a second primary tumor, age, bowel function, and the specific gene. A germline result does not dictate one operation or drug; it adds context to standard oncology decisions.
What Results Mean for Relatives
A confirmed pathogenic PMS2 variant creates a clear cascade-testing opportunity. Adult first-degree relatives—parents, siblings, and children—each usually have a 50% chance of carrying it. More distant relatives may also be at risk through the side of the family from which the variant came.
Targeted familial-variant testing is simpler and more conclusive than repeating a broad panel. A relative who tests positive can begin surveillance before cancer develops. A relative who tests negative for the exact family variant can usually avoid Lynch-specific screening, unless their own history or the other side of the family creates separate risk.
Children are generally not tested for typical Lynch syndrome because surveillance usually starts in adulthood and there is no childhood intervention. Exceptions require specialist input, such as a family with extremely early cancers or concern for constitutional mismatch repair deficiency. When both partners carry pathogenic variants in the same mismatch repair gene, reproductive counseling becomes particularly important.
Family communication can be difficult. A genetics clinic can provide a letter that names the gene, variant, inheritance pattern, and recommended next step without sharing unnecessary medical details. Relatives should receive a copy of the actual report because gene names alone are not enough for accurate targeted testing.
Reproductive options may include natural conception with testing during pregnancy, in vitro fertilization with preimplantation genetic testing, donor eggs or sperm, adoption, or choosing not to test. These are personal choices. Genetic counseling should explain accuracy, limitations, timing, cost, and the difference between avoiding transmission and treating disease.
Limitations and Next Steps
Genetic testing can be technically excellent and still leave uncertainty. A negative result may reflect a truly nonhereditary family pattern, another susceptibility gene, a variant current methods cannot detect, mosaicism, or a tumor process that only mimics Lynch syndrome. Testing quality also differs among laboratories, particularly for copy-number changes and complex gene regions.
Tumor and germline results must be reconciled. If a tumor shows isolated loss of PMS2, although MLH1/PMS2 loss more often points toward MLH1 inactivation but germline testing is negative, the next step may include tumor sequencing for two acquired hits, methylation analysis where appropriate, review of staining quality, or testing another tumor. This prevents an inherited diagnosis from being assigned to someone whose mismatch repair deficiency is confined to the cancer.
After receiving a result:
- Review the exact classification and laboratory methods with a genetics professional.
- Confirm whether the finding is germline, somatic, or uncertain.
- Create a written surveillance schedule with starting ages and intervals.
- Discuss aspirin and risk-reducing surgery only after individualized risk review.
- Share the report with appropriate relatives and arrange targeted testing.
- Revisit the result when guidelines, family history, or variant classification changes.
Seek medical evaluation rather than waiting for the next surveillance visit if there is rectal bleeding, persistent change in bowel habits, unexplained iron-deficiency anemia, postmenopausal bleeding, unusual urinary bleeding, a growing skin lesion, persistent abdominal pain, or unexplained weight loss. Genetic surveillance reduces risk most effectively when it is paired with timely assessment of symptoms.
A well-interpreted PMS2 result can turn a vague family history into a specific prevention plan. Its value comes from matching the laboratory finding to the tumor evidence, the family, and gene-specific management—not from the word “positive” or “negative” alone.
References
- The guidelines for clinical practice for carriers of germline mutations in the Lynch syndrome predisposition genes MLH1, MSH2, MSH6, PMS2 and large deletions of EPCAM 2024 (Guideline)
- Diagnosis and management of Lynch syndrome 2022 (Review)
- Lynch Syndrome – a mechanistic and clinical management update 2022 (Review)
- European guidelines from the EHTG and ESCP for Lynch syndrome: an updated third edition of the Mallorca guidelines based on gene and gender 2021 (Guideline)
- Genetics of Colorectal Cancer (PDQ®) 2025 (Official Report)
Disclaimer
An PMS2 result estimates inherited cancer susceptibility and does not diagnose or exclude cancer by itself. Surveillance and preventive choices should be based on the exact variant classification, personal and family history, and current gene-specific guidance from qualified genetics and oncology professionals. New bleeding, anemia, persistent bowel changes, or other concerning symptoms need medical evaluation even when recent screening was normal.
